The Attorneys General of Nebraska, Indiana, and Louisiana have initiated legal action against the Department of Justice (DoJ) order to reschedule medical cannabis. This lawsuit challenges the federal government’s decision to move cannabis from Schedule I to Schedule III under the Controlled Substances Act, a development previously covered by Hemp Gazette.
The Basis of the Legal Challenge
Nebraska Attorney General Mike Hilgers, Louisiana Attorney General Liz Murrill, and Indiana Attorney General Todd Rokita, all Republicans, filed the lawsuit last week, as reported by Ganjapreneur. Their primary argument is that the medical cannabis rescheduling will facilitate the advancement of adult-use legalization policies at the state level. The suit also raises objections to the potential for expanded medical cannabis production and changes to tax structures under the new federal classification.
The legal challenge targets the DoJ’s follow-up order issued last month, which officially reclassified state-regulated medical cannabis products to Schedule III. This action stemmed from an executive order issued by President Trump in December, calling for the rescheduling. It is important to note that the DoJ’s order specifically pertains to state-regulated medical cannabis products and does not alter the federal status of other forms of cannabis, meaning state-licensed adult-use operators continue to operate in violation of federal law.
Controlled Substances Act Reclassification
The Controlled Substances Act (CSA) categorizes substances into schedules based on their potential for abuse, accepted medical use, and safety. Schedule I is reserved for drugs with “no currently accepted medical use and a high potential for abuse.” The move to Schedule III indicates a federal acknowledgment of some accepted medical use and a lower potential for abuse. The Drug Enforcement Administration (DEA) is reportedly planning hearings to consider further reclassification of cannabis.
State-Level Context and Implications
The lawsuit highlights differing approaches to cannabis policy among the plaintiff states:
- Nebraska: Attorney General Hilgers opposed the 2024 medical cannabis legalization campaign, despite approximately 70% of voters approving the reforms. His re-election opponent, Democrat Jocelyn Brasher, criticized the lawsuit, stating, “Nebraskans should be outraged that taxpayer resources are being spent to challenge the Trump administration’s medical cannabis reform on an issue voters overwhelmingly approved at the ballot box.”
- Louisiana: The state has established a program allowing medical cannabis access for patients with specific debilitating conditions.
- Indiana: Cannabis remains illegal for all purposes, including medical use.
The Attorneys General argue that the federal rescheduling decision will make it easier to push adult-use legalization policies and object to expanded medical cannabis production and tax changes. The outcome of this lawsuit could have significant implications for the future of medical cannabis policy and the broader cannabis industry across the United States.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
